AU2005236068C1 - Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof - Google Patents

Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof Download PDF

Info

Publication number
AU2005236068C1
AU2005236068C1 AU2005236068A AU2005236068A AU2005236068C1 AU 2005236068 C1 AU2005236068 C1 AU 2005236068C1 AU 2005236068 A AU2005236068 A AU 2005236068A AU 2005236068 A AU2005236068 A AU 2005236068A AU 2005236068 C1 AU2005236068 C1 AU 2005236068C1
Authority
AU
Australia
Prior art keywords
pnag
seq
antibody
dpnag
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005236068A
Other languages
English (en)
Other versions
AU2005236068B2 (en
AU2005236068A1 (en
Inventor
Lisa Cavacini
Casie Anne Kelly-Quintos
Gerald B. Pier
Marshall R. Posner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Beth Israel Deaconess Medical Center Inc
Original Assignee
Brigham and Womens Hospital Inc
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Beth Israel Deaconess Medical Center Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2005236068A1 publication Critical patent/AU2005236068A1/en
Publication of AU2005236068B2 publication Critical patent/AU2005236068B2/en
Priority to AU2012205180A priority Critical patent/AU2012205180B2/en
Application granted granted Critical
Publication of AU2005236068C1 publication Critical patent/AU2005236068C1/en
Priority to AU2014277807A priority patent/AU2014277807B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2005236068A 2004-04-21 2005-04-21 Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof Ceased AU2005236068C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2012205180A AU2012205180B2 (en) 2004-04-21 2012-07-17 Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof
AU2014277807A AU2014277807B2 (en) 2004-04-21 2014-12-19 Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56410504P 2004-04-21 2004-04-21
US60/564,105 2004-04-21
PCT/US2005/013694 WO2005103084A2 (en) 2004-04-21 2005-04-21 Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012205180A Division AU2012205180B2 (en) 2004-04-21 2012-07-17 Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof

Publications (3)

Publication Number Publication Date
AU2005236068A1 AU2005236068A1 (en) 2005-11-03
AU2005236068B2 AU2005236068B2 (en) 2012-04-26
AU2005236068C1 true AU2005236068C1 (en) 2012-08-30

Family

ID=35197541

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005236068A Ceased AU2005236068C1 (en) 2004-04-21 2005-04-21 Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof

Country Status (12)

Country Link
US (13) US7786255B2 (https=)
EP (6) EP2455402A1 (https=)
JP (2) JP5080243B2 (https=)
CN (1) CN101001874B (https=)
AU (1) AU2005236068C1 (https=)
CA (1) CA2567748A1 (https=)
DK (1) DK1745075T3 (https=)
ES (2) ES2415358T3 (https=)
PL (1) PL1745075T3 (https=)
PT (1) PT1745075E (https=)
SI (1) SI1745075T1 (https=)
WO (1) WO2005103084A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7047058B1 (en) 2001-02-06 2006-05-16 Medrad, Inc. Apparatuses, systems and methods for extravasation detection
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
WO2004043405A2 (en) * 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
AU2012268821B2 (en) * 2006-06-06 2016-06-02 Janssen Vaccines & Prevention B.V. Human binding molecules having killing activity against staphylococci and uses thereof
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
EP2750595B1 (en) 2011-09-02 2021-02-24 Battelle Memorial Institute Wireless and power-source-free extravasation and infiltration detection sensor
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
US20150086601A1 (en) * 2012-05-07 2015-03-26 Sanofi Methods for preventing biofilm formation
EP2854822B1 (en) * 2012-05-30 2020-07-22 The Brigham and Women's Hospital, Inc. Polysaccharide compositions and methods of use
CN104955840A (zh) * 2012-08-24 2015-09-30 赛诺菲 抗多聚n-乙酰葡糖胺(pnag)单克隆抗体及其用于预防或治疗表达pnag的细菌感染的用途
JPWO2014050518A1 (ja) 2012-09-28 2016-08-22 日本電気株式会社 情報処理装置、情報処理方法および情報処理プログラム
CA2887825A1 (en) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Engineered igg fc domains
WO2014142117A1 (ja) * 2013-03-12 2014-09-18 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
NO2994485T3 (https=) 2013-05-06 2018-06-09
EP2889311B1 (en) 2013-12-30 2018-03-21 Albert-Ludwigs-Universität Freiburg Opsonic and protective monoclonal antibodies against gram-positive pathogens
IL264941B2 (en) 2016-08-24 2025-12-01 Teneobio Inc Transgenic non-human animals producing modified heavy chain-only antibodies
US11597774B2 (en) 2017-05-04 2023-03-07 City Of Hope Antibody variable domains and antibody constructs
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
WO2020167919A1 (en) 2019-02-12 2020-08-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
CN110184231B (zh) * 2019-05-31 2021-02-12 杭州丰海生物科技有限公司 一种胞外分泌pnag多糖的重组枯草芽孢杆菌及其应用
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
US11173199B2 (en) 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
EP4061411A4 (en) * 2019-11-22 2023-11-29 Alopexx, Inc. METHODS FOR PROVIDING CONTINUOUS THERAPY AGAINST PNAG-CONTAINING MICROBES
US10828360B1 (en) 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation
WO2023173020A1 (en) * 2022-03-11 2023-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody materials and methods targeting microbial polysaccharides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003745A2 (en) * 1998-07-15 2000-01-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US20030147809A1 (en) * 2001-12-28 2003-08-07 Jean Gudas Antibodies against the MUC18 antigen
AU2003295520A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US213668A (en) 1879-03-25 Improvement in ice-making apparatus
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4285936A (en) 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4465776A (en) * 1982-09-27 1984-08-14 Research Corporation Monoclonal antibodies to vitamin B6 and immunoassay method
US4652448A (en) 1982-10-07 1987-03-24 Molecular Genetics, Inc. Use of monoclonal antibodies against bacterial adhesins
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4578458A (en) 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
DK219084D0 (da) 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US4786592A (en) 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5589591A (en) 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8621910D0 (en) 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
CA1340506C (en) 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
FR2640628A1 (fr) 1988-12-16 1990-06-22 Commissariat Energie Atomique Oligosaccharides lies (beta)-(1 -> 6) en particulier des 2-acetamido-2-desoxy-glucoses ou - galactoses et leur preparation
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
DK0594743T3 (da) 1991-07-12 1999-12-20 Pfizer Kontinuert cellelinje og vaccine mod aviær coccidia
DE69233012T2 (de) 1991-11-22 2003-11-06 Fattom, Ali Ibrahim Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE156368T1 (de) 1991-12-06 1997-08-15 North Shore Univ Hospital Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen
DK0635132T4 (da) 1992-03-19 2008-08-25 Jackson H M Found Military Med Bredt reaktive opsoniske antistoffer, som reagerer med fælles stafylokok-antigener
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5718694A (en) 1993-11-09 1998-02-17 The Board Of Regents Of The University Of Nebraska Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
CZ292061B6 (cs) * 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
JPH0840932A (ja) 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5830539A (en) 1995-11-17 1998-11-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for functionalizing and coating substrates and devices made according to the methods
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
SK40599A3 (en) * 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
TW586934B (en) 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US5989542A (en) 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
IT1298539B1 (it) 1998-02-03 2000-01-12 Bracco Spa Metodo per la determinazione di infezioni da protesi
JP2002511259A (ja) * 1998-04-09 2002-04-16 ジェンセット ５’ｅｓｔおよびコードされるヒトタンパク質
AU4919699A (en) 1998-07-11 2000-02-01 Mhm Holdings Limited Vehicle seat, vehicle seat table and vehicle communication system
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CA2356849C (en) 1998-12-16 2008-06-03 Sca Hygiene Products Zeist B.V. Acidic superabsorbent polysaccharides
WO2002094983A2 (en) * 2001-05-16 2002-11-28 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US6962813B2 (en) 2001-05-21 2005-11-08 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
JP2005532415A (ja) 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003279308A1 (en) 2002-11-04 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 73a (gpr73a)
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
US8510225B2 (en) 2004-09-01 2013-08-13 Research In Motion Limited Split channel authenticity queries in multi-party dialog
EP2410044B1 (en) 2004-12-29 2022-06-22 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
US8454979B2 (en) 2009-02-20 2013-06-04 Meisho Co., Ltd. Immunopotentiating composition and process for producing same
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
EP2854822B1 (en) 2012-05-30 2020-07-22 The Brigham and Women's Hospital, Inc. Polysaccharide compositions and methods of use
US9759721B2 (en) 2013-01-22 2017-09-12 Imicroq, S.L. Rapid method for detection of pathogen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003745A2 (en) * 1998-07-15 2000-01-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US20030147809A1 (en) * 2001-12-28 2003-08-07 Jean Gudas Antibodies against the MUC18 antigen
US6924360B2 (en) * 2001-12-28 2005-08-02 Abgenix, Inc. Antibodies against the MUC18 antigen
AU2003295520A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOJIMA YOSHIFUMI et al. 'Antibody to the Capsular Polysaccharide/Adhesin Protects Rabbits against catheter-Related Bacteremia Due to Coagulase-Negative Staphylococci.' The Journal of Infectious Diseases. Vol. 162, No. 2, pages 435-441 *
LEE, JEAN C. et al. 'Protective Efficacy of Antibodies to the Staphylococcus aureus Type 5 Capsular Polysaccharide in a Modified Model of Endocarditis in Rats.' Infection and Immunity. 1997, Vol. 65, No. 10, pages 4146-4151 *
MAIRA-LITRAN, TOMAS et al. 'Immunochemical Properties of the Staphylococcal Poly-NAcetylglucosamine Surface Polysaccharide.' Infection and Immunity. 2002, Vol. 70, No. 8, pages 4433-4440 *

Also Published As

Publication number Publication date
US20170226194A1 (en) 2017-08-10
US20210363228A1 (en) 2021-11-25
US10906962B2 (en) 2021-02-02
AU2005236068B2 (en) 2012-04-26
US20130243806A1 (en) 2013-09-19
US20120201833A1 (en) 2012-08-09
US20190127448A1 (en) 2019-05-02
JP2008501317A (ja) 2008-01-24
WO2005103084A2 (en) 2005-11-03
EP2455400A1 (en) 2012-05-23
EP2455401B1 (en) 2018-01-24
US8912314B2 (en) 2014-12-16
JP2011224023A (ja) 2011-11-10
US8350017B2 (en) 2013-01-08
CN101001874A (zh) 2007-07-18
AU2005236068A1 (en) 2005-11-03
EP1745075B1 (en) 2013-04-03
US20110274700A1 (en) 2011-11-10
EP2468769A1 (en) 2012-06-27
PT1745075E (pt) 2013-06-17
ES2415358T3 (es) 2013-07-25
EP2455402A1 (en) 2012-05-23
SI1745075T1 (sl) 2013-07-31
PL1745075T3 (pl) 2013-09-30
CA2567748A1 (en) 2005-11-03
US9458227B2 (en) 2016-10-04
JP5080243B2 (ja) 2012-11-21
US8461319B2 (en) 2013-06-11
JP5717582B2 (ja) 2015-05-13
US8252894B2 (en) 2012-08-28
DK1745075T3 (da) 2013-06-24
ES2738112T3 (es) 2020-01-20
HK1100369A1 (en) 2007-09-21
US20110002932A1 (en) 2011-01-06
EP2455401A1 (en) 2012-05-23
EP1745075A2 (en) 2007-01-24
US8084595B2 (en) 2011-12-27
EP2455400B1 (en) 2019-03-20
US7786255B2 (en) 2010-08-31
CN101001874B (zh) 2012-12-19
US20150329620A1 (en) 2015-11-19
WO2005103084A3 (en) 2006-02-16
US8410249B2 (en) 2013-04-02
EP2439213A1 (en) 2012-04-11
US10017563B2 (en) 2018-07-10
US8435515B2 (en) 2013-05-07
US20120201834A1 (en) 2012-08-09
US20230382980A1 (en) 2023-11-30
US20060115486A1 (en) 2006-06-01
EP2439213B1 (en) 2018-12-12
US20120208270A1 (en) 2012-08-16
US20120196359A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
US20230382980A1 (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
AU2014277807B2 (en) Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof
AU2012205180B2 (en) Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof
HK1169423A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
HK1168859A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
HK1172044A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
HK1171762A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding antibodies
HK1171762B (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding antibodies
HK1171763A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
HK1100369B (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 APR 2012.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 APR 2012

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired